H

ello, everyone, and how are you this morning? We are doing just fine, thank you, despite some noisy construction near the otherwise serene Pharmalot campus. Our focus remains intact, however, courtesy of a few cups of stimulation and, as always, we invite you to join us. Remember, no prescription is required, which means you do not have to be concerned with understanding rebates and copayments. And you can celebrate this happy reality while scanning some tidbits. Hope your day goes well and, of course, do keep in touch …

A federal judge pushing for a settlement in lawsuits seeking to hold drug makers responsible for their roles in the U.S. opioid epidemic set an aggressive schedule that would have the first trial take place in March 2019, Reuters says. The lawsuits accuse the drug makers of deceptively marketing opioids and allege that wholesalers ignored red flags indicating the painkillers were being diverted for improper uses. Three cases were picked for bellwether trials that are used in mass litigation to help both sides gauge the range of damages and define settlement options.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy